Quantitation of aggregates in therapeutic proteins using sedimentation velocity analytical ultracentrifugation: Practical considerations that affect precision and accuracy
被引:59
作者:
Pekar, Allen
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly & Co, Biopharmaceut Res & Dev, Indianapolis, IN 46285 USAEli Lilly & Co, Biopharmaceut Res & Dev, Indianapolis, IN 46285 USA
Pekar, Allen
[1
]
Sukumar, Muppalla
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly & Co, Biopharmaceut Res & Dev, Indianapolis, IN 46285 USAEli Lilly & Co, Biopharmaceut Res & Dev, Indianapolis, IN 46285 USA
Sukumar, Muppalla
[1
]
机构:
[1] Eli Lilly & Co, Biopharmaceut Res & Dev, Indianapolis, IN 46285 USA
analytical control strategy;
AUC;
biopharmaceutical;
immunogenicity;
protein formulation;
SEC;
sedfit;
sedphat;
D O I:
10.1016/j.ab.2007.04.035
中图分类号:
Q5 [生物化学];
学科分类号:
071010 ;
081704 ;
摘要:
Aggregation is a major degradation pathway that needs to be characterized and controlled during the development of protein pharmaceuticals. Analytical ultiacentrifugation-sedimentation velocity (AUC-SV) is emerging as an important orthogonal tool to size exclusion chromatography to quantitate aggregates. However, the precision and accuracy of modern AUC-SV and the experimental variables that influence these two performance parameters need to be better understood and controlled. To understand the impact of experimental and data analysis variables on the precision, aggregate content in monoclonal antibody preparations was measured by AUC-SV and analyzed by the software program Sedfit. Accuracy and limit of detection were evaluated by spiking a known quantity of a sample enriched in aggregate fraction. The results suggest experimental and data analysis approaches that improve precision and accuracy of aggregate quantitation by AUC-SV. Both precision and accuracy were found to be highly dependent on the quality of the centerpieces as assessed by microscopic examination. The level of precision for quantitating aggregates was found to be approximately +/- 0.3 to 0.7% over the aggregate content range of approximately 0.6 to 67%. Accuracy, as indicated by approximately 80 to 90% spiked recovery, could be achieved down to aggregate levels as low as approximately 1.5%, whereas the limits of detection and quantitation appear to be approximately 0.2 and 0.6%, respectively. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:225 / 237
页数:13
相关论文
共 32 条
[1]
BARTH HG, 1994, ANAL CHEM, V66, pR595, DOI 10.1021/ac00084a022
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Clodfelter, DK
Pekar, AH
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Pekar, AH
Rebhun, DM
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Rebhun, DM
Destrampe, KA
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Destrampe, KA
Havel, HA
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Havel, HA
Myers, SR
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Myers, SR
Brader, ML
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USAEli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Clodfelter, DK
Pekar, AH
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Pekar, AH
Rebhun, DM
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Rebhun, DM
Destrampe, KA
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Destrampe, KA
Havel, HA
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Havel, HA
Myers, SR
论文数: 0引用数: 0
h-index: 0
机构:Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA
Myers, SR
Brader, ML
论文数: 0引用数: 0
h-index: 0
机构:
Eli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USAEli Lilly & Co, Lilly Res Labs, Biopharmaceut Dev, Indianapolis, IN 46285 USA